Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytotoxic intracavitary chemotherapy.

M Markman

    The American Journal of the Medical Sciences
    |March 1, 1986
    PubMed
    Summary

    Intracavitary chemotherapy delivers anti-cancer drugs directly into body cavities, offering higher drug exposure than plasma. This approach shows promise for microscopic residual disease and preventing intraperitoneal recurrence, despite risks like chemical serositis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Differences in Discounting Behavior and Brain Responses for Food and Money Reward.

    eNeuro·2024
    Same author

    Apical hypertrophic cardiomyopathy: A case series at a Brazilian referral center with a maximal follow-up of 15 years.

    Annales de cardiologie et d'angeiologie·2021
    Same author

    Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

    European journal of gynaecological oncology·2018
    Same author

    Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

    Current oncology (Toronto, Ont.)·2018
    Same author

    Surgical intervention in relapsed ovarian cancer is beneficial: contra.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011

    Area of Science:

    • Oncology
    • Pharmacology
    • Surgical Oncology

    Background:

    • Intracavitary chemotherapy involves administering cytotoxic agents directly into body cavities for localized tumor treatment.
    • Theoretical advantages include enhanced drug concentration within the cavity compared to plasma levels.

    Purpose of the Study:

    • To evaluate the pharmacokinetic advantages and clinical utility of intracavitary chemotherapy.
    • To identify potential applications and toxicities of this therapeutic strategy.

    Main Methods:

    • Pharmacokinetic evaluation of antineoplastic drugs administered intracavitarily.
    • Modeling predictions to assess drug exposure in cavities versus plasma.
    • Review of potential patient populations and associated toxicities.

    Main Results:

    • Pharmacokinetic studies confirmed higher drug concentrations in body cavities than in plasma.
    • Limited direct tissue penetration of intracavitary agents was observed.
    • Identified potential toxicities including chemical serositis (abdominal pain) and infection.

    Conclusions:

    • Intracavitary chemotherapy offers a theoretical advantage for treating tumors confined to body cavities.
    • This approach is most promising for microscopic residual disease post-surgery or for high-risk intraperitoneal recurrence.
    • Further clinical evaluation is necessary to establish its role in cancer management.

    Related Experiment Videos